Covidien plc (COV) [Rocket]

In millions, except per share items	Sep-26-14	Sep-27-13	Sep-28-12	Sep-30-11	Sep-24-10	Sep-25-09	Sep-26-08	Sep-28-07
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Revenues:
Medical Devices	9,091.0	8,689.0	8,308.0	7,829.0	6,715.0	6,061.0		5,213.0
United States	5,284.0	5,103.0	4,929.0		5,725.0	5,925.0		5,400.0
Non-U.S. Developed Markets	3,734.0	3,649.0	3,640.0
Emerging Markets	1,641.0	1,483.0	1,282.0
Other				1,778.0
Total revenues	10,659.0	10,235.0	9,851.0	9,607.0	10,429.0	10,263.0	9,910.0	9,317.0
Revenue growth [+]	4.1%	3.9%	2.5%	-7.9%	1.6%	3.6%	6.4%	12.1%
Medical Devices	4.6%	4.6%	6.1%	16.6%	10.8%			-6.7%
United States	3.5%	3.5%			-3.4%			10.3%
Non-U.S. Developed Markets	2.3%	0.2%
Emerging Markets	10.7%	15.7%
Pharmaceuticals					-5.0%
Cost of goods sold	4,332.0	4,150.0	3,944.0	3,886.0	4,624.0	4,622.0	4,601.0	4,593.0
Gross profit	6,327.0	6,085.0	5,907.0	5,721.0	5,805.0	5,641.0	5,309.0	4,724.0
Gross margin	59.4%	59.5%	60.0%	59.6%	55.7%	55.0%	53.6%	50.7%
Selling, general and administrative	3,657.0	3,340.0	3,261.0	3,153.0	3,219.0	3,042.0	2,881.0	2,488.0
Research and development	546.0	508.0	479.0	412.0	447.0	427.0	341.0	267.0
Other operating expenses	-107.0					183.0	42.0	1,202.0
EBITDA [+]	2,811.0	2,879.0	2,800.0	2,755.0	2,628.0	2,408.0	2,443.0	1,148.0
EBITDA growth	-2.4%	2.8%	1.6%	4.8%	9.1%	-1.4%	112.8%	-52.0%
EBITDA margin	26.4%	28.1%	28.4%	28.7%	25.2%	23.5%	24.7%	12.3%
Depreciation and amortization	580.0	642.0	633.0	599.0	489.0	419.0	398.0	381.0
EBIT [+]	2,231.0	2,237.0	2,167.0	2,156.0	2,139.0	1,989.0	2,045.0	767.0
EBIT growth	-0.3%	3.2%	0.5%	0.8%	7.5%	-2.7%	166.6%	-62.9%
EBIT margin	20.9%	21.9%	22.0%	22.4%	20.5%	19.4%	20.6%	8.2%
Non-recurring items [+]	239.0	105.0	82.0	114.0	76.0	176.0	99.0	129.0
Asset impairment	94.0							34.0
In-process research & development						115.0	22.0	38.0
Interest expense, net [+]	189.0	192.0	191.0	184.0	177.0	151.0	166.0	152.0
Interest expense	204.0	208.0	206.0	203.0	199.0	175.0	209.0	188.0
Interest income	15.0	16.0	15.0	19.0	22.0	24.0	43.0	36.0
Other income (expense), net	20.0	89.0	25.0	22.0	40.0	145.0	199.0	-135.0
Pre-tax income	1,823.0	2,029.0	1,919.0	1,880.0	1,926.0	1,807.0	1,979.0	351.0
Income taxes	161.0	429.0	282.0	299.0	363.0	865.0	536.0	485.0
Tax rate	8.8%	21.1%	14.7%	15.9%	18.8%	47.9%	27.1%	138.2%
Earnings from continuing ops	1,662.0	1,600.0	1,637.0	1,581.0	1,563.0	942.0	1,443.0	-134.0
Earnings from discontinued ops						-35.0	-82.0	-208.0
Net income	1,662.0	1,700.0	1,905.0	1,868.0	1,632.0	907.0	1,361.0	-342.0
Net margin	15.6%	16.6%	19.3%	19.4%	15.6%	8.8%	13.7%	-3.7%

Basic EPS [+]	$3.69	$3.43	$3.40	$3.21	$3.13	$1.87	$2.89	($0.27)
Growth	7.6%	0.7%	6.1%	2.6%	66.9%	-35.1%	-1170.4%	-109.4%
Diluted EPS [+]	$3.64	$3.40	$3.37	$3.18	$3.10	$1.87	$2.86	($0.27)
Growth	7.3%	0.9%	5.9%	2.6%	66.3%	-34.7%	-1159.8%	-109.4%

Dividends per share [+]	$1.28	$1.04	$0.90	$0.80	$0.72	$0.64	$0.64
Growth	22.9%	15.6%	12.3%	11.6%	12.5%	0.0%

Shares outstanding (basic) [+]	451.0	467.0	481.0	493.0	500.0	503.0	500.0	497.0
Growth	-3.4%	-2.9%	-2.4%	-1.4%	-0.6%	0.6%	0.6%	0.0%
Shares outstanding (diluted) [+]	456.0	471.0	486.0	497.0	504.0	505.0	505.0	497.0
Growth	-3.2%	-3.1%	-2.2%	-1.4%	-0.2%	0.0%	1.6%	0.0%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.